Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR174 | Q9BXC1 | 19/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15450411 | 0.95 | GPR174 (0.91) | GPR174MAPTTDP1MEN1KMT2A | |
| SCHEMBL22388511 | 0.90 | GPR174 (1.00) | GPR174MAPTTDP1MEN1KMT2A | |
| SCHEMBL22388540 | 0.87 | GPR174 (1.00) | GPR174MAPTTDP1MEN1KMT2A | |
| SCHEMBL22388478 | 0.86 | GPR174 (1.00) | GPR174MAPTTDP1MEN1KMT2A | |
| SCHEMBL22388491 | 0.86 | GPR174 (1.00) | GPR174MAPTTDP1MEN1KMT2A | |
| SCHEMBL22388492 | 0.86 | GPR174 (1.00) | GPR174MAPTTDP1MEN1KMT2A | |
| SCHEMBL22388487 | 0.85 | GPR174 (1.00) | GPR174MAPTTDP1MEN1KMT2A | |
| SCHEMBL15450412 | 0.85 | GPR174 (0.90) | GPR174MAPTTDP1MEN1KMT2A | |
| SCHEMBL15450418 | 0.84 | GPR174 (0.72) | GPR174MAPTTDP1MEN1KMT2A | |
| SCHEMBL15450468 | 0.84 | GPR174 (0.72) | GPR174MAPTTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321083-A1 | Inhibitors of GPR174 and Uses Thereof | OMEROS CORP (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| US-20200345725-A1 | Methods and Compositions for Treating Cancer | OMEROS CORPORATOIN | 2020-11-05 | — | — | US | disclosed |
| US-20200276190-A1 | Inhibitors of GPR174 and Uses Thereof | OMEROS CORP (US) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276190-A1 | Inhibitors of GPR174 and Uses Thereof | GPR174, GPR4, GPR88 | GPR174 1/4885MAPT 2149/4885TDP1 3897/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | GPR174 2962/4885MAPT 3945/4885TDP1 1517/4885 |
| US-20230321083-A1 | Inhibitors of GPR174 and Uses Thereof | GPR174, GPR4, GPR88 | GPR174 1/4885MAPT 2149/4885TDP1 3897/4885 |
| US-20200345725-A1 | Methods and Compositions for Treating Cancer | LPAR5, LPAR3, LPAR1 | GPR174 37/4885MAPT 3312/4885TDP1 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.